Prof. Dr. Shaobing Hua | Medicine and Dentistry | Best Innovation Award
Hangzhou Dalton Biosciences Ltd | China
Prof. Dr. Shaobing Hua is a distinguished biomedical scientist and innovator whose career spans more than three decades of impactful contributions to molecular biology, therapeutic antibody discovery, and advanced diagnostic technologies. Trained as a molecular biologist with postdoctoral experience at leading U.S. research institutions, he has played a pivotal role in translating fundamental discoveries into clinically deployable solutions. His early work advanced the understanding of signal transduction, proteasome regulation, and gene expression in protozoan parasites, laying the foundation for subsequent research in therapeutic antibody platforms, which led to multiple U.S. and international patents for novel humanized antibodies and high-throughput screening methods. Prof. Hua is widely recognized for developing next-generation hybrid capture technologies and innovative HPV testing platforms that have transformed cervical cancer screening, particularly in resource-limited settings. Under his scientific leadership, DALTON BioSciences has introduced a suite of diagnostic products for cervical cancer, endometrial carcinoma, pre-eclampsia, and vaginitis, contributing to the health of nearly 30 million women. His portfolio includes over 30 peer-reviewed publications in journals such as Journal of Biological Chemistry, Clinical Cancer Research, Protein Science, and Oncogene, and several dozens of patents granted in the United States, China, and the PCT system. His work has been cited widely by researchers across molecular diagnostics, oncology, and immunotechnology. Throughout his career, Prof. Hua has collaborated extensively with major clinical institutions, including leading hospitals affiliated with Zhejiang University, Peking University, the Chinese Academy of Medical Sciences, and several provincial oncology centers. He has served in key roles in national research programs, including China’s 863 Program, national key research plans, and major public health initiatives focused on cervical cancer elimination. His contributions have significantly advanced women’s health diagnostics, strengthened public health infrastructures, and accelerated the global adoption of innovative molecular screening technologies. Prof. Hua’s research, leadership, and translational impact continue to shape the future of precision diagnostics and global health innovation.
Profile: ORCID
Featured Publications
Liu, S., Han, B., Jin, D. Q., Li, L. W., Ge, T. T., Shou, Y. J., Ye, J. M., Zhang, L., & Hua, S. B. (2025). Design and development of a target amplification-free microfluidic platform for multiplex nucleic acids detection: A new generation of hybrid capture immunoassay. Journal of Medical Virology.
Ding, L., Lin, Y. H., Azam, M., Sheridan, J., Wei, S., Gupta, G., Singh, R. K., Pauling, M. H., Chu, A., Tran, A., Yu, N., Hu, J., Wang, W., Long, H., Xiang, D., Zhu, L., & Hua, S. B. (2010). Generation of high-affinity fully human anti-human interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Science, 19, 1957–1966.
Vaday, G. G., Hua, S. B., Peehl, D. M., Pauling, M. H., Lin, Y. H., Zhu, L., Lawrence, D. M., Foda, H. D., & Zucker, S. (2004). CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single-chain Fv antibodies. Clinical Cancer Research, 10, 5630–5639.
Xia, C., Ma, W., Wang, F., Hua, S. B., & Liu, M. (2001). Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene, 20, 5903–5907.
Xia, C., Bao, Z., Tabassam, F., Ma, W., Qiu, M., Hua, S. B., & Liu, M. (2000). GCIP, a novel human Grap2 and Cyclin D interacting protein, regulates E2F-mediated transcriptional activity. Journal of Biological Chemistry, 275, 20942–20948.